MSK Immuno-Oncology for the Translational Researcher Short Course

MSK 斯隆免疫肿瘤学转化研究人员短期课程

• 批准号: 10350643
• 负责人: Ushma Neill
• 金额: $ 32.28万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-04-01 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10350643
• 关键词: Antibody Therapy; Awareness; Biological Markers; Blocking Antibodies; Cancer Biology; Caring; Cell Therapy; Clinic; Clinical; Clinical Trials; Clinical Trials Design; Communities; Dedications; Development; Diagnostic; Education; Educational workshop; Ensure; Exposure to; Eye; Faculty; Fostering; Foundations; Funding; Generations; Goals; Hematologic Neoplasms; Immunocompetent; Immunologics; Immunology; Immunooncology; Immunotherapeutic agent; Immunotherapy; Investments; Journals; Knowledge; Learning; Malignant Neoplasms; Memorial Sloan-Kettering Cancer Center; Mentors; Mentorship; Modernization; Needles; New York; Oncologist; Participant; Patients; Perception; Physicians; Research; Research Personnel; Role; Science; Scientist; Shapes; T-Lymphocyte; Techniques; Technology; Therapeutic; Therapeutic Agents; Training; Translational Research; anti-PD-L1 antibodies; anticancer research; arm; base; cancer education; cancer therapy; chimeric antigen receptor T cells; clinical application; clinical care; clinical practice; design; education research; efficacy evaluation; experience; immune checkpoint blockade; improved; innovation; insight; interest; lectures; lens; next generation; novel; novel therapeutics; programmed cell death protein 1; programs; radiological imaging; recruit; skills; tool; training opportunity; translational scientist; trial design; tumor immunology

UE5 MSK Immuno-Oncology for the Translational Researcher Short Course: Project Summary / Abstract The MSK Immuno-Oncology for the Translational Researcher Short Course (ITRSC) is a cancer education research experience that will enable eligible junior NCI-funded faculty to learn about tumor immunology, current immunotherapy-based clinical practice and cutting-edge translational research under the mentorship of expert MSK faculty. Program participants will attend a 3-day workshop onsite in New York, led by those centrally involved in basic and clinical immuno-oncology research. ITRSC participants will also have an opportunity to seek additional mentorship and guidance from world experts on immuno-oncology. We anticipate that for some of the ITRSC participants, this short course will be their first substantive exposure to immuno-oncology; for others, the deep dive into clinical aspects of complications, trial design and standards of therapy will be eye-opening. By providing them with a concentrated and intense exposure to immuno- oncology, we will ensure that they will have the proper understanding to apply their clinical and scientific skills to help develop novel research ideas and clinical trials with a better understanding of immunological concepts. A key goal of this program is to increase the junior faculty’s awareness of and interest in immuno-oncology research and give the perspective and concrete tools to tackle the most pertinent immuno-oncology questions at the interface between clinic and lab. Through strategic recruitment of NCI-funded scientists and physicians and exposure to carefully selected mentors and research topics, the ITRSC will provide a path toward development of cancer biologists capable of informing the vanguard of cancer biology and therapeutics. The ITRSC will enhance the participants’ knowledge about cancer, immunology, and their critical intersection by pursuing the following Specific Aims: 1. Develop a course to form a deep understanding of innovative immuno-oncology through lectures and hands on exposure to experimental techniques. 2. Provide NCI grantees additional mentorship and guidance in both clinical and translational immuno- oncology research in order to foster the trainees’ interest and engagement in academic immuno- oncology research. 3. Evaluate the efficacy of intensive training opportunities in shaping immuno-oncology research. Through the exposure that the ITRSC will enable, we expect to shape the faculty’s perception of immunology applied to cancer research and clinical practice such that many will pursue intensive research in this field.

UE 5 MSK Immuno-Oncology for the Translational Researcher Short Course：项目摘要/ 摘要 MSK免疫肿瘤学转化研究员短期课程（ITRSC）是一种癌症教育 研究经验，将使合格的初级NCI资助的教师了解肿瘤免疫学， 目前基于免疫治疗的临床实践和尖端的转化研究的指导下， MSK专家项目参与者将在纽约参加为期3天的现场研讨会，由 主要参与基础和临床免疫肿瘤学研究。ITRSC参与者还将获得 有机会从世界免疫肿瘤学专家那里寻求更多的指导和指导。 我们预计，对于ITRSC的一些参与者来说，这个短期课程将是他们第一次实质性的接触 对其他人来说，深入研究并发症、试验设计和标准的临床方面 会让你大开眼界通过向他们提供集中和强烈的免疫- 肿瘤学，我们将确保他们将有适当的理解，以应用他们的临床和科学技能， 帮助开发新的研究思路和临床试验，更好地理解免疫学概念。 该计划的一个主要目标是提高初级教师对免疫肿瘤学的认识和兴趣 研究并给出解决最相关的免疫肿瘤学问题的观点和具体工具 在诊所和实验室之间的接口。通过战略性招聘NCI资助的科学家和医生 并接触精心挑选的导师和研究课题，ITRSC将提供一条通往 培养能够为癌症生物学和治疗学提供信息的癌症生物学家。 ITRSC将提高参与者对癌症，免疫学及其关键交叉点的了解 通过追求以下具体目标： 1.开发一门课程，通过讲座形成对创新免疫肿瘤学的深刻理解， 接触实验技术。 2.在临床和转化免疫学方面为NCI受资助者提供额外的指导和指导， 肿瘤学研究，以培养学员对学术免疫学的兴趣和参与， 肿瘤学研究 3.评估强化培训机会在塑造免疫肿瘤学研究中的有效性。 通过ITRSC的曝光，我们希望塑造教师对免疫学的看法 应用于癌症研究和临床实践，因此许多人将在该领域进行深入研究。